MannKind Announces FDA Acknowledgement Of Resubmission Of New Drug Application For AFREZZA

MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for AFREZZA ® (insulin human [rDNA origin]) Inhalation Powder. The FDA considered the updated NDA to be a complete class 2 response to its Complete Response Letter issued in January 2011 and assigned a user fee goal date of April 15, 2014.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA ® , has completed Phase 3 clinical trials. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Copyright Business Wire 2010

If you liked this article you might like

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind in Free Fall After Changes to Insulin Product, Sales Force